We have highlighted some clinical trials that were opened since the beginning of 2014. There are many others that are also underway. You can find them on ClinicalTrials.gov. Each trial has a specific purpose related to aplastic anemia, MDS, or PNH. Should you consider a clinical trial? Ask your doctor or contact the study coordinators for further information. Learn more in the Clinical Trials section.
To find out more about clinical trials at specific institutions near you, check their websites. Large academic healthcare institutions often identify the clinical trials being run by their researchers. Here is an example from MD Anderson.
Search for aplastic anemia studies actively recruiting patients. The following are a sample of the 67 studies that are actively recruiting aplastic anemia patients.
Title/Link to more information |
Study Purpose |
Study Coordinator |
Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease | Some treatments for cancer or other diseases can lead to infertility in women. These treatments include chemotherapy, some stem cell transplants, and pelvic radiotherapy. They are called gonadotoxic therapies. Women can now have their eggs frozen before they have these treatments. This may allow them to get pregnant later. Researchers want to learn more about this technology and processes. This study if for women at least 18 years old who are past puberty and before menopause. They must be scheduled to have gonadotoxic therapies. |
National Institutes of Health Clinical Center Contact: Christine L Atallah, R.N. (301) 435-7926 christine.atallah@nih.gov Please refer to this study by its ClinicalTrials.gov identifier: NCT02225145 |
Seach for myelodysplastic syndromes studies actively recruiting patients. The following MDS studies are a sample of the 288 open studies that are actively recruiting MDS patients.
Title/Link to more information |
Study Purpose |
Study Coordinator |
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) |
The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety of each study drug given on these schedules will also be studied. | This study is being conducted at MD Anderson Cancer Center Contact: Elias Jabbour, MD, 713-792-4764 Please refer to this study by its ClinicalTrials.gov identifier: NCT02269280 |
Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) | The goal of this clinical research study is to compare how well two different schedules of giving busulfan with fludarabine and cladribine before a stem cell transplant in patients with AML or MDS may help to control the disease. The safety of this drug combination will also be studied. | This study is being conducted at MD Anderson Cancer Center Contact: Uday Popat, MD 713-792-8750 Please refer to this study by its ClinicalTrials.gov identifier: NCT02250937 |
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes |
This study is being performed to assess the safety, tolerability, and preliminary clinical effects of BVD-523 given orally, twice daily for 21-day cycles, in patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). | This study is being conducted at he University of Texas MD Anderson Cancer Center Contact: Thomas Medina, RN, 713-745-1847 TEMedina@mdanderson.org Please refer to this study by its ClinicalTrials.gov identifier: NCT02296242 |
Search for a list of current paroxysmal nocturnal hemoglobinuria studies actively recruiting patients. The following are a sample of the 11 open studies for PNH patients in the United States.
Title/Link to more information |
Study Purpose |
Study Coordinator |
This study is a collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal Hemoglobinuria (PNH). |
Johns Hopkins University Medical Center , Baltimore Contact: Lynn Sanders 203-439-9609 sandersl@alxn.com Please refer to this study by its ClinicalTrials.gov identifier: NCT01374360 |